Sab bio announces founding of clinical advisory board to guide the development of sab-142 for type 1 diabetes

Miami, aug. 05, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs) (the “company” or “sab”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced the founding of a clinical advisory board to provide expert insight and guidance to the company in the clinical development of sab-142, its leading therapeutic candidate.
SABS Ratings Summary
SABS Quant Ranking